Celltrion HealthCare Co Ltd (091990)

Overview

Celltrion Healthcare Co., Ltd., headquartered in Incheon, South Korea, specializes in the manufacture, processing, and global distribution of biosimilar and biological medicines. Originally established in 1999 under the name Nexol, Inc., the company underwent a rebranding to its current name in March 2009. It is dedicated to providing advanced therapeutic solutions, targeting a variety of serious diseases, to patients worldwide. As of December 28, 2023, Celltrion Healthcare functions as a subsidiary of Celltrion, Inc., emphasizing its substantial role within the larger biopharmaceutical landscape.

Products and Services

Celltrion Healthcare Co., Ltd. offers a range of biosimilar medicines catering to multiple therapeutic areas:

• Remsima: A monoclonal antibody biosimilar designed for the treatment of various autoimmune diseases. It is indicated for conditions such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, both adult and children's Crohn's disease, psoriasis, and psoriatic arthritis. Remsima represents a pioneering effort in making biologic treatments more accessible to patients suffering from autoimmune disorders.
• Truxima: This biosimilar targets lymphoma and chronic lymphocytic leukemia, as well as autoimmune diseases like Wegener's granulomatosis and microscopic polyangiitis, in addition to rheumatoid arthritis. Truxima highlights Celltrion Healthcare’s ability to provide vital medicines for both cancer and autoimmune conditions, expanding treatment options for patients worldwide.
• Herzuma: Approved for the treatment of metastatic breast cancer, early breast cancer, and metastatic gastric cancer, Herzuma embodies Celltrion Healthcare’s commitment to fighting cancer. By providing a biosimilar option for these conditions, Herzuma helps to improve access to essential cancer therapies.
• Remsima SC: An innovative subcutaneous formulation of Remsima for the treatment of rheumatoid arthritis, this product showcases Celltrion Healthcare’s dedication to improving patient convenience and treatment adherence through advanced drug delivery systems.